EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Successful Treatment of Refractory IgA‐Mediated Autoimmune Hemolytic Anemia With Bortezomib

Silvia Neri iD, Corien L Eckhardt, Boukje M Beuger, Folman Folman, Eva Rettenbacher, Hanke L Matlung, Taco W Kuijpers, Josephine M I Vos, Robin van Bruggen iD

eJHaem · 2025-12 · 6 (6)

DOI: 10.1002/jha2.70162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eJHaem, online erschienen am 25.10.2025. Verfasst von Silvia Neri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sanquin Research and Landsteiner Laboratory of the Academic Medical Center University of Amsterdam Amsterdam the Netherlands. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

IgA‐mediated autoimmune hemolytic anemia (AIHA) is a rare condition associated with severe hemolysis and limited therapeutic response. Bortezomib, a proteasome inhibitor, targets plasma cells responsible for autoantibody production. Here, we describe a case of refractory IgA‐mediated AIHA in a 13‐year‐old boy presenting with severe hemolysis, who was successfully treated with bortezomib.

Methods

Blood samples were collected at different time points throughout the disease course for immunohematology testing.

Results

The patient showed significant hematologic improvement following four doses of Bortezomib with reduction in hemolysis and recovery of hemoglobin levels. Laboratory tests revealed complement‐negative, Coombs‐positive blood tests combined with altered RBC morphology. Phagocytosis of patient's RBC was absent at all timepoints. Notably, despite hematologic improvement, IgA‐positive RBC remained present, accompanied by compensated hemolysis.

Conclusions

The present case demonstrates the potential of bortezomib as a treatment option for refractory AIHA cases, particularly in children. Trial Registration : The authors have confirmed clinical trial registration is not needed for this submission

Autor:innen und Institutionen

  • Sanquin Research and Landsteiner Laboratory of the Academic Medical Center University of Amsterdam Amsterdam the Netherlands.
  • Department of Pediatric Hematology Location Academic Medical Center (AMC), Emma Children's Hospital, Amsterdam UMC, University of Amsterdam Amsterdam the Netherlands.
  • Department of Pediatric Infectious Disease Location Academic Medical Center (AMC), Emma Children's Hospital, Amsterdam UMC, University of Amsterdam Amsterdam the Netherlands.
  • Sanquin Diagnostic Services Amsterdam the Netherlands.
  • Department of Hematology Amsterdam UMC, University of Amsterdam Amsterdam the Netherlands.

ORCID-Profile: Silvia Neri, Robin van Bruggen

Zitieren

APA

Neri, S., Eckhardt, C. L., Beuger, B. M., Folman, F., Rettenbacher, E., Matlung, H. L., Kuijpers, T. W., Vos, J. M. I., & van Bruggen, R. (2025). Successful Treatment of Refractory IgA‐Mediated Autoimmune Hemolytic Anemia With Bortezomib. eJHaem, 6(6). https://doi.org/10.1002/jha2.70162

Vancouver

Neri S, Eckhardt CL, Beuger BM, Folman F, Rettenbacher E, Matlung HL, et al. Successful Treatment of Refractory IgA‐Mediated Autoimmune Hemolytic Anemia With Bortezomib. eJHaem. 2025;6(6). doi:10.1002/jha2.70162

BibTeX
@article{Neri2025,
  author = {Neri, Silvia and Eckhardt, Corien L and Beuger, Boukje M and Folman, Folman and Rettenbacher, Eva and Matlung, Hanke L and Kuijpers, Taco W and Vos, Josephine M I and van Bruggen, Robin},
  title = {Successful Treatment of Refractory IgA‐Mediated Autoimmune Hemolytic Anemia With Bortezomib},
  journal = {eJHaem},
  year = {2025},
  volume = {6},
  number = {6},
  doi = {10.1002/jha2.70162}
}
Kostenlos starten →